<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">34293864</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>21</Day></DateCompleted><DateRevised><Year>2022</Year><Month>08</Month><Day>13</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1520-4804</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>15</Issue><PubDate><Year>2021</Year><Month>Aug</Month><Day>12</Day></PubDate></JournalIssue><Title>Journal of medicinal chemistry</Title><ISOAbbreviation>J Med Chem</ISOAbbreviation></Journal><ArticleTitle>NMR-Guided Design of Potent and Selective EphA4 Agonistic Ligands.</ArticleTitle><Pagination><StartPage>11229</StartPage><EndPage>11246</EndPage><MedlinePgn>11229-11246</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1021/acs.jmedchem.1c00608</ELocationID><Abstract><AbstractText>In this paper, we applied an innovative nuclear magnetic resonance (NMR)-guided screening and ligand design approach, named focused high-throughput screening by NMR (fHTS by NMR), to derive potent, low-molecular-weight ligands capable of mimicking interactions elicited by ephrin ligands on the receptor tyrosine kinase EphA4. The agents bind with nanomolar affinity, trigger receptor activation in cellular assays with motor neurons, and provide remarkable motor neuron protection from amyotrophic lateral sclerosis (ALS) patient-derived astrocytes. Structural studies on the complex between EphA4 ligand-binding domain and a most active agent provide insights into the mechanism of the agents at a molecular level. Together with preliminary in vivo pharmacology studies, the data form a strong foundation for the translation of these agents for the treatment of ALS and potentially other human diseases.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Baggio</LastName><ForeName>Carlo</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Biomedical Sciences, School of Medicine, University of California, Riverside, 900 University Avenue, Riverside, California 92521, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kulinich</LastName><ForeName>Anna</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Biomedical Sciences, School of Medicine, University of California, Riverside, 900 University Avenue, Riverside, California 92521, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dennys</LastName><ForeName>Cassandra N</ForeName><Initials>CN</Initials><AffiliationInfo><Affiliation>Nationwide Children's Hospital, 700 Children's Drive, Columbus, Ohio 43205, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodrigo</LastName><ForeName>Rochelle</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Nationwide Children's Hospital, 700 Children's Drive, Columbus, Ohio 43205, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Kathrin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Nationwide Children's Hospital, 700 Children's Drive, Columbus, Ohio 43205, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ethell</LastName><ForeName>Iryna</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Division of Biomedical Sciences, School of Medicine, University of California, Riverside, 900 University Avenue, Riverside, California 92521, United States.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pellecchia</LastName><ForeName>Maurizio</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-5179-470X</Identifier><AffiliationInfo><Affiliation>Division of Biomedical Sciences, School of Medicine, University of California, Riverside, 900 University Avenue, Riverside, California 92521, United States.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P20 CA242620</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>P41 GM103311</GrantID><Acronym>GM</Acronym><Agency>NIGMS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 CA168517</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS107479</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>07</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Med Chem</MedlineTA><NlmUniqueID>9716531</NlmUniqueID><ISSNLinking>0022-2623</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000596">Amino Acids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000656353">EPHA4 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005449">Fluorenes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D008024">Ligands</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 2.7.10.1</RegistryNumber><NameOfSubstance UI="D036122">Receptor, EphA4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000596" MajorTopicYN="N">Amino Acids</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018360" MajorTopicYN="N">Crystallography, X-Ray</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004305" MajorTopicYN="N">Dose-Response Relationship, Drug</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015195" MajorTopicYN="Y">Drug Design</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005449" MajorTopicYN="N">Fluorenes</DescriptorName><QualifierName UI="Q000737" MajorTopicYN="N">chemistry</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057166" MajorTopicYN="N">High-Throughput Screening Assays</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008024" MajorTopicYN="N">Ligands</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009682" MajorTopicYN="N">Magnetic Resonance Spectroscopy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008958" MajorTopicYN="N">Models, Molecular</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015394" MajorTopicYN="N">Molecular Structure</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D036122" MajorTopicYN="N">Receptor, EphA4</DescriptorName><QualifierName UI="Q000819" MajorTopicYN="Y">agonists</QualifierName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013329" MajorTopicYN="N">Structure-Activity Relationship</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013816" MajorTopicYN="N">Thermodynamics</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>23</Day><Hour>5</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34293864</ArticleId><ArticleId IdType="mid">NIHMS1748117</ArticleId><ArticleId IdType="pmc">PMC8555409</ArticleId><ArticleId IdType="doi">10.1021/acs.jmedchem.1c00608</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Van Hoecke A; Schoonaert L; Lemmens R; Timmers M; Staats KA; Laird AS; Peeters E; Philips T; Goris A; Dubois B; Andersen PM; Al-Chalabi A; Thijs V; Turnley AM; van Vught PW; Veldink JH; Hardiman O; Van Den Bosch L; Gonzalez-Perez P; Van Damme P; Brown RH Jr.; van den Berg LH; Robberecht W, EphA4 Is a Disease Modifier of Amyotrophic Lateral Sclerosis in Animal Models and in Humans. Nature medicine 2012, 18 (9), 1418&#x2013;1422.</Citation><ArticleIdList><ArticleId IdType="pubmed">22922411</ArticleId></ArticleIdList></Reference><Reference><Citation>Rue L; Oeckl P; Timmers M; Lenaerts A; van der Vos J; Smolders S; Poppe L; de Boer A; Van Den Bosch L; Van Damme P; Weishaupt JH; Ludolph AC; Otto M; Robberecht W; Lemmens R, Reduction of Ephrin-A5 Aggravates Disease Progression in Amyotrophic Lateral Sclerosis. Acta Neuropathol Commun 2019, 7 (1), 114.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6626434</ArticleId><ArticleId IdType="pubmed">31300041</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu B; De SK; Kulinich A; Salem AF; Koeppen J; Wang R; Barile E; Wang S; Zhang D; Ethell I; Pellecchia M, Potent and Selective Epha4 Agonists for the Treatment of ALS. Cell Chem Biol 2017, 24 (3), 293&#x2013;305.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6522132</ArticleId><ArticleId IdType="pubmed">28196613</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu B; Barile E; De SK; Wei J; Purves A; Pellecchia M, High-Throughput Screening by Nuclear Magnetic Resonance (HTS by NMR) for the Identification of PPIs Antagonists. Curr Top Med Chem 2015, 15 (20), 2032&#x2013;2042.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4545611</ArticleId><ArticleId IdType="pubmed">25986689</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu B; Zhang Z; Noberini R; Barile E; Giulianotti M; Pinilla C; Houghten RA; Pasquale EB; Pellecchia M, HTS by NMR of Combinatorial Libraries: A Fragment-Based Approach to Ligand Discovery. Chemistry &amp; biology 2013, 20 (1), 19&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3966493</ArticleId><ArticleId IdType="pubmed">23352136</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinilla C; Appel JR; Blanc P; Houghten RA, Rapid Identification of High Affinity Peptide Ligands Using Positional Scanning Synthetic Peptide Combinatorial Libraries. Biotechniques 1992, 13 (6), 901&#x2013;905.</Citation><ArticleIdList><ArticleId IdType="pubmed">1476743</ArticleId></ArticleIdList></Reference><Reference><Citation>Barile E; Pellecchia M, Nmr-Based Approaches for the Identification and Optimization of Inhibitors of Protein-Protein Interactions. Chem Rev 2014, 114 (9), 4749&#x2013;4763.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4027952</ArticleId><ArticleId IdType="pubmed">24712885</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggio C; Cerofolini L; Fragai M; Luchinat C; Pellecchia M, HTS by NMR for the Identification of Potent and Selective Inhibitors of Metalloenzymes. ACS Med Chem Lett 2018, 9 (2), 137&#x2013;142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5807865</ArticleId><ArticleId IdType="pubmed">29456802</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggio C; Velazquez JV; Fragai M; Nordgren TM; Pellecchia M, Therapeutic Targeting of Mmp-12 for the Treatment of Chronic Obstructive Pulmonary Disease. J Med Chem 2020, 63 (21), 12911&#x2013;12920.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8544245</ArticleId><ArticleId IdType="pubmed">33107733</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggio C; Gambini L; Udompholkul P; Salem AF; Aronson A; Dona A; Troadec E; Pichiorri F; Pellecchia M, Design of Potent Pan-IAP and Lys-Covalent Xiap Selective Inhibitors Using a Thermodynamics Driven Approach. J Med Chem 2018, 61 (14), 6350&#x2013;6363.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7583350</ArticleId><ArticleId IdType="pubmed">29940121</ArticleId></ArticleIdList></Reference><Reference><Citation>Rue L; Timmers M; Lenaerts A; Smolders S; Poppe L; de Boer A; Van Den Bosch L; Van Damme P; Robberecht W; Lemmens R, Reducing Epha4 before Disease Onset Does Not Affect Survival in a Mouse Model of Amyotrophic Lateral Sclerosis. Sci Rep 2019, 9 (1), 14112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6773754</ArticleId><ArticleId IdType="pubmed">31575928</ArticleId></ArticleIdList></Reference><Reference><Citation>Murai KK; Nguyen LN; Koolpe M; McLennan R; Krull CE; Pasquale EB, Targeting the Epha4 Receptor in the Nervous System with Biologically Active Peptides. Molecular and cellular neurosciences 2003, 24 (4), 1000&#x2013;1011.</Citation><ArticleIdList><ArticleId IdType="pubmed">14697664</ArticleId></ArticleIdList></Reference><Reference><Citation>Noberini R; Koolpe M; Peddibhotla S; Dahl R; Su Y; Cosford ND; Roth GP; Pasquale EB, Small Molecules Can Selectively Inhibit Ephrin Binding to the EphA4 and EphA2 Receptors. The Journal of biological chemistry 2008, 283 (43), 29461&#x2013;29472.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2570887</ArticleId><ArticleId IdType="pubmed">18728010</ArticleId></ArticleIdList></Reference><Reference><Citation>Tognolini M; Incerti M; Lodola A, Are We Using the Right Pharmacological Tools to Target EphA4? ACS Chem Neurosci 2014, 5 (12), 1146&#x2013;1147.</Citation><ArticleIdList><ArticleId IdType="pubmed">25405504</ArticleId></ArticleIdList></Reference><Reference><Citation>Noberini R; De SK; Zhang Z; Wu B; Raveendra-Panickar D; Chen V; Vazquez J; Qin H; Song J; Cosford ND; Pellecchia M; Pasquale EB, A Disalicylic Acid-Furanyl Derivative Inhibits Ephrin Binding to a Subset of Eph Receptors. Chem Biol Drug Des 2011, 78 (4), 667&#x2013;678.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3196665</ArticleId><ArticleId IdType="pubmed">21791013</ArticleId></ArticleIdList></Reference><Reference><Citation>Olson EJ; Lechtenberg BC; Zhao C; Rubio de la Torre E; Lamberto I; Riedl SJ; Dawson PE; Pasquale EB, Modifications of a Nanomolar Cyclic Peptide Antagonist for the EphA4 Receptor to Achieve High Plasma Stability. ACS Med Chem Lett 2016, 7 (9), 841&#x2013;846.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5018863</ArticleId><ArticleId IdType="pubmed">27660688</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J; Cooper LT; Boyd AW; Bartlett PF, Decreased Signalling of Epha4 Improves Functional Performance and Motor Neuron Survival in the SOD1(G93A) ALS Mouse Model. Sci Rep 2018, 8 (1), 11393.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6065374</ArticleId><ArticleId IdType="pubmed">30061574</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasquale EB, Eph-Ephrin Bidirectional Signaling in Physiology and Disease. Cell 2008, 133 (1), 38&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">18394988</ArticleId></ArticleIdList></Reference><Reference><Citation>Furne C; Ricard J; Cabrera JR; Pays L; Bethea JR; Mehlen P; Liebl DJ, Ephrinb3 Is an Anti-Apoptotic Ligand That Inhibits the Dependence Receptor Functions of EphA4 Receptors During Adult Neurogenesis. Biochim Biophys Acta 2009, 1793 (2), 231&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2631096</ArticleId><ArticleId IdType="pubmed">18948148</ArticleId></ArticleIdList></Reference><Reference><Citation>Baggio C; Udompholkul P; Barile E; Pellecchia M, Enthalpy-Based Screening of Focused Combinatorial Libraries for the Identification of Potent and Selective Ligands. ACS Chem Biol 2017, 12 (12), 2981&#x2013;2989.</Citation><ArticleIdList><ArticleId IdType="pubmed">29094589</ArticleId></ArticleIdList></Reference><Reference><Citation>Ran X; Gestwicki JE, Inhibitors of Protein-Protein Interactions (PPIs): An Analysis of Scaffold Choices and Buried Surface Area. Curr Opin Chem Biol 2018, 44, 75&#x2013;86.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6066447</ArticleId><ArticleId IdType="pubmed">29908451</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowden TA; Aricescu AR; Nettleship JE; Siebold C; Rahman-Huq N; Owens RJ; Stuart DI; Jones EY, Structural Plasticity of Eph Receptor A4 Facilitates Cross-Class Ephrin Signaling. Structure 2009, 17 (10), 1386&#x2013;1397.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2832735</ArticleId><ArticleId IdType="pubmed">19836338</ArticleId></ArticleIdList></Reference><Reference><Citation>Forse GJ; Uson ML; Nasertorabi F; Kolatkar A; Lamberto I; Pasquale EB; Kuhn P, Distinctive Structure of the EphA3/Ephrin-A5 Complex Reveals a Dual Mode of Eph Receptor Interaction for Ephrin-A5. PLoS One 2015, 10 (5), e0127081.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4439037</ArticleId><ArticleId IdType="pubmed">25993310</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Giorgio FP; Carrasco MA; Siao MC; Maniatis T; Eggan K, Non-Cell Autonomous Effect of Glia on Motor Neurons in an Embryonic Stem Cell-Based ALS Model. Nat Neurosci 2007, 10 (5), 608&#x2013;614.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3139463</ArticleId><ArticleId IdType="pubmed">17435754</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagai M; Re DB; Nagata T; Chalazonitis A; Jessell TM; Wichterle H; Przedborski S, Astrocytes Expressing Als-Linked Mutated SOD1 Release Factors Selectively Toxic to Motor Neurons. Nat Neurosci 2007, 10 (5), 615&#x2013;622.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3799799</ArticleId><ArticleId IdType="pubmed">17435755</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamanaka K; Chun SJ; Boillee S; Fujimori-Tonou N; Yamashita H; Gutmann DH; Takahashi R; Misawa H; Cleveland DW, Astrocytes as Determinants of Disease Progression in Inherited Amyotrophic Lateral Sclerosis. Nat Neurosci 2008, 11 (3), 251&#x2013;253.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3137510</ArticleId><ArticleId IdType="pubmed">18246065</ArticleId></ArticleIdList></Reference><Reference><Citation>Di Giorgio FP; Boulting GL; Bobrowicz S; Eggan KC, Human Embryonic Stem Cell-Derived Motor Neurons Are Sensitive to the Toxic Effect of Glial Cells Carrying an Als-Causing Mutation. Cell Stem Cell 2008, 3 (6), 637&#x2013;648.</Citation><ArticleIdList><ArticleId IdType="pubmed">19041780</ArticleId></ArticleIdList></Reference><Reference><Citation>Marchetto MC; Muotri AR; Mu Y; Smith AM; Cezar GG; Gage FH, Non-Cell-Autonomous Effect of Human SOD1 G37R Astrocytes on Motor Neurons Derived from Human Embryonic Stem Cells. Cell Stem Cell 2008, 3 (6), 649&#x2013;657.</Citation><ArticleIdList><ArticleId IdType="pubmed">19041781</ArticleId></ArticleIdList></Reference><Reference><Citation>Haidet-Phillips AM; Hester ME; Miranda CJ; Meyer K; Braun L; Frakes A; Song S; Likhite S; Murtha MJ; Foust KD; Rao M; Eagle A; Kammesheidt A; Christensen A; Mendell JR; Burghes AH; Kaspar BK, Astrocytes from Familial and Sporadic ALS Patients Are Toxic to Motor Neurons. Nat Biotechnol 2011, 29 (9), 824&#x2013;828.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3170425</ArticleId><ArticleId IdType="pubmed">21832997</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer K; Ferraiuolo L; Miranda CJ; Likhite S; McElroy S; Renusch S; Ditsworth D; Lagier-Tourenne C; Smith RA; Ravits J; Burghes AH; Shaw PJ; Cleveland DW; Kolb SJ; Kaspar BK, Direct Conversion of Patient Fibroblasts Demonstrates Non-Cell Autonomous Toxicity of Astrocytes to Motor Neurons in Familial and Sporadic Als. Proc Natl Acad Sci U S A 2014, 111 (2), 829&#x2013;832.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3896192</ArticleId><ArticleId IdType="pubmed">24379375</ArticleId></ArticleIdList></Reference><Reference><Citation>Boyd AW; Bartlett PF; Lackmann M, Therapeutic Targeting of Eph Receptors and Their Ligands. Nat Rev Drug Discov 2014, 13 (1), 39&#x2013;62.</Citation><ArticleIdList><ArticleId IdType="pubmed">24378802</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamberto I; Qin H; Noberini R; Premkumar L; Bourgin C; Riedl SJ; Song J; Pasquale EB, Distinctive Binding of Three Antagonistic Peptides to the Ephrin-Binding Pocket of the EphA4 Receptor. The Biochemical journal 2012, 445 (1), 47&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3677027</ArticleId><ArticleId IdType="pubmed">22489865</ArticleId></ArticleIdList></Reference><Reference><Citation>Lamberto I; Lechtenberg BC; Olson EJ; Mace PD; Dawson PE; Riedl SJ; Pasquale EB, Development and Structural Analysis of a Nanomolar Cyclic Peptide Antagonist for the EphA4 Receptor. ACS chemical biology 2014, 9 (12), 2787&#x2013;2795.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4273976</ArticleId><ArticleId IdType="pubmed">25268696</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu K; Tzvetkova-Robev D; Xu Y; Goldgur Y; Chan YP; Himanen JP; Nikolov DB, Insights into Eph Receptor Tyrosine Kinase Activation from Crystal Structures of the EphA4 Ectodomain and Its Complex with Ephrin-A5. Proc Natl Acad Sci U S A 2013, 110 (36), 14634&#x2013;14639.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3767517</ArticleId><ArticleId IdType="pubmed">23959867</ArticleId></ArticleIdList></Reference><Reference><Citation>Li JJ; Liu DP; Liu GT; Xie D, Ephrina5 Acts as a Tumor Suppressor in Glioma by Negative Regulation of Epidermal Growth Factor Receptor. Oncogene 2009, 28 (15), 1759&#x2013;1768.</Citation><ArticleIdList><ArticleId IdType="pubmed">19270726</ArticleId></ArticleIdList></Reference><Reference><Citation>Pensold D; Gehrmann J; Pitschelatow G; Walberg A; Braunsteffer K; Reichard J; Ravaei A; Linde J; Lampert A; Costa IG; Zimmer-Bensch G, The Expression of the Cancer-Associated Lncrna Snhg15 Is Modulated by EphrinA5-Induced Signaling. Int J Mol Sci 2021, 22 (3).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7866228</ArticleId><ArticleId IdType="pubmed">33572758</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang TH; Chang JL; Ho JY; Wu HC; Chen TC, Ephrina5 Suppresses Colon Cancer Development by Negatively Regulating Epidermal Growth Factor Receptor Stability. FEBS J 2012, 279 (2), 251&#x2013;263.</Citation><ArticleIdList><ArticleId IdType="pubmed">22074469</ArticleId></ArticleIdList></Reference><Reference><Citation>Fu AK; Hung KW; Huang H; Gu S; Shen Y; Cheng EY; Ip FC; Huang X; Fu WY; Ip NY, Blockade of EphA4 Signaling Ameliorates Hippocampal Synaptic Dysfunctions in Mouse Models of Alzheimer&#x2019;s Disease. Proceedings of the National Academy of Sciences of the United States of America 2014, 111 (27), 9959&#x2013;9964.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4103318</ArticleId><ArticleId IdType="pubmed">24958880</ArticleId></ArticleIdList></Reference><Reference><Citation>Spanevello MD; Tajouri SI; Mirciov C; Kurniawan N; Pearse MJ; Fabri LJ; Owczarek CM; Hardy MP; Bradford RA; Ramunno ML; Turnley AM; Ruitenberg MJ; Boyd AW; Bartlett PF, Acute Delivery of EphA4-Fc Improves Functional Recovery after Contusive Spinal Cord Injury in Rats. J Neurotrauma 2013, 30 (12), 1023&#x2013;1034.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3689926</ArticleId><ArticleId IdType="pubmed">23557244</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanell A; Clausen F; Djupsjo A; Vallstedt A; Patra K; Israelsson C; Larhammar M; Bjork M; Paixao S; Kullander K; Marklund N, Functional and Histological Outcome after Focal Traumatic Brain Injury Is Not Improved in Conditional EphA4 Knockout Mice. J Neurotrauma 2012, 29 (17), 2660&#x2013;2671.</Citation><ArticleIdList><ArticleId IdType="pubmed">22985250</ArticleId></ArticleIdList></Reference><Reference><Citation>Frugier T; Conquest A; McLean C; Currie P; Moses D; Goldshmit Y, Expression and Activation of EphA4 in the Human Brain after Traumatic Injury. J Neuropathol Exp Neurol 2012, 71 (3), 242&#x2013;250.</Citation><ArticleIdList><ArticleId IdType="pubmed">22318127</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukai J; Yokote H; Yamanaka R; Arao T; Nishio K; Itakura T, Epha4 Promotes Cell Proliferation and Migration through a Novel EphA4-Fgfr1 Signaling Pathway in the Human Glioma U251 Cell Line. Mol Cancer Ther 2008, 7 (9), 2768&#x2013;2778.</Citation><ArticleIdList><ArticleId IdType="pubmed">18790757</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyazaki K; Inokuchi M; Takagi Y; Kato K; Kojima K; Sugihara K, EphA4 Is a Prognostic Factor in Gastric Cancer. BMC Clin Pathol 2013, 13 (1), 19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3720259</ArticleId><ArticleId IdType="pubmed">23738943</ArticleId></ArticleIdList></Reference><Reference><Citation>Oshima T; Akaike M; Yoshihara K; Shiozawa M; Yamamoto N; Sato T; Akihito N; Nagano Y; Fujii S; Kunisaki C; Wada N; Rino Y; Tanaka K; Masuda M; Imada T, Overexpression of EphA4 Gene and Reduced Expression of EphB2 Gene Correlates with Liver Metastasis in Colorectal Cancer. Int J Oncol 2008, 33 (3), 573&#x2013;577.</Citation><ArticleIdList><ArticleId IdType="pubmed">18695888</ArticleId></ArticleIdList></Reference><Reference><Citation>Iiizumi M; Hosokawa M; Takehara A; Chung S; Nakamura T; Katagiri T; Eguchi H; Ohigashi H; Ishikawa O; Nakamura Y; Nakagawa H, EphA4 Receptor, Overexpressed in Pancreatic Ductal Adenocarcinoma, Promotes Cancer Cell Growth. Cancer Sci 2006, 97 (11), 1211&#x2013;1216.</Citation><ArticleIdList><ArticleId IdType="pubmed">16965393</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>